GSK to Buy Canada's Bellus Health for $2 Bln

Reuters2023-04-18

April 18 (Reuters) - GSK Plc will buy Canada-based drug development company Bellus Health Inc in an all-cash deal for $2 billion, the companies said on Tuesday, as the British pharmaceuticals maker bets on respiratory therapies.

GSK's offer of $14.75 per share is more than double Bellus' closing price of $7.26 on the Nasdaq on Monday.

The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with refractory chronic cough (RCC).

The acquisition is expected to be accretive to GSK's adjusted earnings per share from 2027 following the anticipated regulatory approval and launch of camlipixant in 2026.

"Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential," said GSK chief commercial officer Luke Miels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Bubikhoo
2023-04-18
Bubikhoo
Ok

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2328226551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-04-18 15:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2328226551","market":"us","top_or_hot":-1,"title":"GSK to Buy Canada's Bellus Health for $2 Bln","media":"Reuters","content":"<html><head></head><body><p style=\"text-align: start;\">April 18 (Reuters) - GSK Plc will buy Canada-based drug development company Bellus Health Inc in an all-cash deal for $2 billion, the companies said on Tuesday, as the British pharmaceuticals maker bets on respiratory therapies.</p><p style=\"text-align: start;\">GSK&#39;s offer of $14.75 per share is more than double Bellus&#39; closing price of $7.26 on the Nasdaq on Monday.</p><p style=\"text-align: start;\">The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with refractory chronic cough (RCC).</p><p>The acquisition is expected to be accretive to GSK&#39;s adjusted earnings per share from 2027 following the anticipated regulatory approval and launch of camlipixant in 2026.</p><p style=\"text-align: start;\">&#34;Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,&#34; said GSK chief commercial officer Luke Miels.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK to Buy Canada's Bellus Health for $2 Bln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK to Buy Canada's Bellus Health for $2 Bln\n</h2>\n\n<h4 class=\"meta\">\n\n2023-04-18 15:33 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>April 18 (Reuters) - GSK Plc will buy Canada-based drug development company Bellus Health Inc in an all-cash deal for $2 billion, the companies said on Tuesday, as the British pharmaceuticals maker ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"2328226551","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2328226551","pubTimestamp":1681803201,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"April 18 (Reuters) - GSK Plc will buy Canada-based drug development company Bellus Health Inc in an ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4007":"制药","BK4588":"碎股","BK4532":"文艺复兴科技持仓"},"translate_title":"葛兰素史克将以20亿美元收购加拿大Bellus Health","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLU":0.9},"content_text":"April 18 (Reuters) - GSK Plc will buy Canada-based drug development company Bellus Health Inc in an all-cash deal for $2 billion, the companies said on Tuesday, as the British pharmaceuticals maker bets on respiratory therapies.GSK's offer of $14.75 per share is more than double Bellus' closing price of $7.26 on the Nasdaq on Monday.The acquisition gives GSK access to camlipixant, which is in late-stage development for the first-line treatment of adult patients with refractory chronic cough (RCC).The acquisition is expected to be accretive to GSK's adjusted earnings per share from 2027 following the anticipated regulatory approval and launch of camlipixant in 2026.\"Camlipixant, a novel, highly selective P2X3 antagonist, has the potential to be a best-in-class treatment with significant sales potential,\" said GSK chief commercial officer Luke Miels.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9944870576,"gmtCreate":1681805303396,"gmtModify":1681805305486,"author":{"id":"3576837410161825","authorId":"3576837410161825","name":"Bubikhoo","avatar":"https://static.tigerbbs.com/3247ebd81f7b901adc64183ed4fe7458","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":8,"crmLevelSwitch":1,"idStr":"3576837410161825","authorIdStr":"3576837410161825"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9944870576","repostId":2328226551,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":4,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2328226551"}